Eventide Asset Management, LLC Xencor Inc Transaction History

Eventide Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$19.74 - $29.01 $9.88 Million - $14.5 Million	-500,755 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$26.68 - $41.63 $139,936 - $218,349	-5,245 Reduced 1.04%	500,755 $13.4 Million
Q4 2020 Feb 16, 2021	BUY	$36.63 - $47.63 $7.55 Million - $9.81 Million	206,000 Added 68.67%	506,000 $22.1 Million
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $2.87 Million - $3.97 Million	97,000 Added 47.78%	300,000 $12.3 Million
Q4 2018 Feb 14, 2019	SELL	$32.39 - $42.05 $809,750 - $1.05 Million	-25,000 Reduced 10.96%	203,000 $7.34 Million
Q1 2018 May 15, 2018	SELL	$21.18 - $33.78 $1.8 Million - $2.87 Million	-85,000 Reduced 27.16%	228,000 $6.84 Million
Q3 2017 Nov 14, 2017	BUY	$19.61 - $23.35 $6.14 Million - $7.31 Million	313,000	313,000 $7.17 Million

216

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.59B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.